Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D L Behrens

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Cancer Research|July 1, 1992
Inhibition of dihydroorotate dehydrogenase activity by brequinar sodiumS F Chen, F W Perrella, D L Behrens, et al.
Journal of Medicinal Chemistry|July 8, 1994
Phospholipase C inhibitors: a new class of cytotoxic agentsF W Perrella, S F Chen, D L Behrens, et al.
Cancer Research|January 15, 1988
Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrateJ L Gross, D L Behrens, D E Mullins, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Distribution of the novel anticancer drug candidate Brequinar sodium (DuP 785, NSC 368390) into normal and tumor tissues of nude mice bearing human colon carcinoma xenograftsH S Shen, S F Chen, D L Behrens, et al.
Nucleic Acids Research|May 15, 1996
Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide librariesS P Ho, D H Britton, B A Stone, et al.
Cancer Research|April 15, 1994
(R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitroM R Kirshenbaum, S F Chen, C H Behrens, et al.
Anti-Cancer Drugs|August 1, 1993
XB596, a promising bis-naphthalimide anti-cancer agentS F Chen, D L Behrens, C H Behrens, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Cancer Research|July 1, 1992
Inhibition of dihydroorotate dehydrogenase activity by brequinar sodiumS F Chen, F W Perrella, D L Behrens, et al.
Journal of Medicinal Chemistry|July 8, 1994
Phospholipase C inhibitors: a new class of cytotoxic agentsF W Perrella, S F Chen, D L Behrens, et al.
Cancer Research|January 15, 1988
Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrateJ L Gross, D L Behrens, D E Mullins, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Distribution of the novel anticancer drug candidate Brequinar sodium (DuP 785, NSC 368390) into normal and tumor tissues of nude mice bearing human colon carcinoma xenograftsH S Shen, S F Chen, D L Behrens, et al.
Nucleic Acids Research|May 15, 1996
Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide librariesS P Ho, D H Britton, B A Stone, et al.
Cancer Research|April 15, 1994
(R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitroM R Kirshenbaum, S F Chen, C H Behrens, et al.
Anti-Cancer Drugs|August 1, 1993
XB596, a promising bis-naphthalimide anti-cancer agentS F Chen, D L Behrens, C H Behrens, et al.
Pageof 1